LUZHU BIOTECH-B (02480) Receives Clinical Trial Approval in China for Recombinant RSV Vaccine
Stock News
1 hour ago
LUZHU BIOTECH-B (02480) has announced that its group-developed recombinant respiratory syncytial virus (RSV) vaccine has been approved by the National Medical Products Administration of the People's Republic of China to commence clinical trials in China.
The product is a recombinant protein vaccine candidate independently developed by the group for the prevention of lower respiratory tract disease (LRTD) caused by RSV.
It is a liquid formulation aluminum-adjuvanted vaccine that utilizes the RSV pre-fusion F (Pre-F) protein antigen.
The approval of this clinical trial has laid a solid foundation for the group's subsequent development of recombinant protein vaccine candidates.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.